Detalhe da pesquisa
1.
Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.
Int J Clin Oncol
; 24(6): 660-665, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31011915
2.
Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine.
Biopharm Drug Dispos
; 39(1): 38-46, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29055025
3.
Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer-effect of renal insufficiency.
Jpn J Clin Oncol
; 47(5): 407-412, 2017 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28159957
4.
Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.
Drug Metab Dispos
; 42(9): 1485-92, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25002745
5.
Involvement of concentrative nucleoside transporter 1 in intestinal absorption of trifluorothymidine, a novel antitumor nucleoside, in rats.
J Pharmacol Exp Ther
; 340(2): 457-62, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22076553
6.
A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114.
CPT Pharmacometrics Syst Pharmacol
; 11(5): 604-615, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34951129
7.
Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
Drug Metab Dispos
; 38(8): 1267-76, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20463005
8.
TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy.
Mol Cancer Ther
; 17(8): 1683-1693, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29748212
9.
Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.
Cancer Chemother Pharmacol
; 79(1): 107-116, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27933371
10.
Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells.
J Pharm Sci
; 104(9): 3146-53, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25900515
11.
Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse.
Cancer Chemother Pharmacol
; 76(2): 325-33, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26084259
12.
Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys.
J Pharm Pharmacol
; 66(12): 1686-97, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25117829
13.
First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers.
Cancer Chemother Pharmacol
; 73(3): 577-83, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24452393
14.
Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes.
Pharmacol Res Perspect
; 1(1): e00009, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25505563
15.
Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
J Pharm Pharmacol
; 61(12): 1643-51, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19958587
16.
The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling.
Pharm Res
; 25(8): 1891-901, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18483837